SR13668 [2,10-Dicarbethoxy-6-methoxy-5,7-dihydro-indolo-(2,3-b)carbazole] has been proven effective in cancer prevention, but the limited bioavailability has hindered its clinical translation. In this study, we have developed a continuous, scalable process to form stable poly(lactic-co-glycolic acid) nanoparticles encapsulating SR13668, based on understanding of the competitive kinetics of nanoprecipitation and spray drying. The optimized formulation achieved high drug loading (33.3wt %) and small particles (150nm) with narrow size distribution. The prepared nanoparticle suspensions through flash nanoprecipitation were spray dried to achieve long-term stability and to conveniently adjust the nanoparticle concentration before use. In vitro release of SR13668 from the nanosuspensions was measured in a solution with separated organic and aqueous phases to overcome the limit of SR13668 low water solubility. Higher oral bioavailability of SR13668 by employing polymeric nanoparticles compared with the Labrasol® formulation was demonstrated in a mouse model.
|Number of pages||9|
|Journal||Journal of Pharmaceutical Sciences|
|Publication status||Published - 2012 Oct|
Bibliographical noteFunding Information:
The study was supported by National Cancer Institute, Department of Health and Human Services (contract number N01‐CN‐43306). The authors are grateful to Dr. Yoon Yeo at Purdue University for the access of the spray dryer in her laboratory.
All Science Journal Classification (ASJC) codes
- Pharmaceutical Science